title: References - Neonatal Intensive Care Drug Manual
text: |
  Neonatal Intensive Care Drug Manual
  |
  bet | 519/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  References
  |
  Novoa M, Baselga E, Beltran S, Giraldo L, Shahbaz A, Pardo-Hernandez H, Arevalo-Rodriguez I. Interventions for infantile haemangiomas of the skin. Cochrane Database Syst Rev. 2018;4:CD006545.
  Lou Y, Peng WJ, Cao Y, Cao DS, Xie J, Li HH. The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. Br J Clin Pharmacol. 2014;78:44-57.
  Broeks IJ, Hermans DJ, Dassel AC, van der Vleuten CJ, van Beynum IM. Propranolol treatment in life-threatening airway hemangiomas: a case series and review of literature. Int J Pediatr Otorhinolaryngol. 2013;77:1791-800.
  Kaempfen S, Neumann RP, Jost K, Schulzke SM. Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev. 2018;3:CD011893.
  Filippi L, Cavallaro G, Bagnoli P, Dal Monte M, Fiorini P, Donzelli G, Tinelli F, Araimo G, Cristofori G, la Marca G, Della Bona ML, La Torre A, Fortunato P, Furlanetto S, Osnaghi S, Mosca F. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr. 2013;163:1570-7 e6.
  Korkmaz L, Bastug O, Ozdemir A, Korkut S, Karaca C, Akin MA, Gunes T, Kurtoglu S, Ozturk MA. The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index. Curr Eye Res. 2017;42:88-97.
  Sanghvi KP, Kabra NS, Padhi P, Singh U, Dash SK, Avasthi BS. Prophylactic propranolol for prevention of ROP and visual outcome at 1 year (PreROP trial). Arch Dis Child Fetal Neonatal Ed. 2017;102:F389-F94.
  Ahuja RS, Ramakrishnan S, Kothari SS, Bhatt K, Gupta SK, Juneja R, Saxena A, Bahl VK. Propranolol in infants with ventricular septal defect with heart failure(VSD-phf study). Annals of Pediatric Cardiology. 2013;6 (1):105-6.
  Buchhorn R, Hulpke-Wette M, Hilgers R, Bartmus D, Wessel A, Bursch J. Propranolol treatment of congestive heart failure in infants with congenital heart disease: The CHF-PRO-INFANT Trial. Congestive heart failure in infants treated with propanol. Int J Cardiol. 2001;79:167-73.
  Alabed S, Sabouni A, Al Dakhoul S, Bdaiwi Y, Frobel-Mercier AK. Beta-blockers for congestive heart failure in children. Cochrane Database Syst Rev. 2016:CD007037.
  Sanatani S, Potts JE, Reed JH, Saul JP, Stephenson EA, Gibbs KA, Anderson CC, Mackie AS, Ro PS, Tisma-Dupanovic S, Kanter RJ, Batra AS, Fournier A, Blaufox AD, Singh HR, Ross BA, Wong KK, Bar-Cohen Y, McCrindle BW, Etheridge SP. The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. Circ Arrhythm Electrophysiol. 2012;5:984-91.
  Hornik CP, Chu PY, Li JS, Clark RH, Smith PB, Hill KD. Comparative effectiveness of digoxin and propranolol for supraventricular tachycardia in infants. Pediatr Crit Care Med. 2014;15:839-45.
  Bolin EH, Lang SM, Tang X, Collins RT. Propranolol Versus Digoxin in the Neonate for Supraventricular Tachycardia (from the Pediatric Health Information System). Am J Cardiol. 2017;119:1605-10.
  ANZCOR Guideline 12.5 – Management of Specific Dysrhythmias in Paediatric Advanced Life Support. https://resus.org.au/wpfb-file/anzcor-guideline-12-5-management-of-spec-dys-aug16-pdf/ 2016.
  Brugada J, Blom N, Sarquella-Brugada G, Blomstrom-Lundqvist C, Deanfield J, Janousek J, Abrams D, Bauersfeld U, Brugada R, Drago F, De Groot N, Happonen JM, Hebe J, Yen Ho S, Marijon E, Paul T, Pfammatter JP, Rosenthal E. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15:1337-82.
  Ravisankar S, Kuehn D, Clark RH, Greenberg RG, Smith PB, Hornik CP. Antihypertensive drug exposure in premature infants from 1997 to 2013. Cardiology in the Young. 2017;27:905-11.
  Robinson RF, Nahata MC, Batisky DL, Mahan JD. Pharmacologic treatment of chronic pediatric hypertension. Paediatr Drugs. 2005;7:27-40.
  Mladenka P, Applova L, Patocka J, Costa VM, Remiao F, Pourova J, Mladenka A, Karlickova J, Jahodar L, Voprsalova M, Varner KJ, Sterba M. Comprehensive review of cardiovascular toxicity of drugs and related agents. Medicinal Research Reviews. 2018;38:1332-403.
  Fanous E, Mogyorosy G. Does the prophylactic and therapeutic use of beta-blockers in preoperative patients with tetralogy of Fallot significantly prevent and treat the occurrence of cyanotic spells? Interactive Cardiovascular and Thoracic Surgery. 2017;25:647-50.
  Garson A, Jr., Gillette PC, McNamara DG. Propranolol: the preferred palliation for tetralogy of Fallot. Am J Cardiol. 1981;47:1098-104.
  Deal JE, Sever PS, Barratt TM, Dillon MJ. Phaeochromocytoma - Investigation and management of 10 cases. Archives of Disease in Childhood. 1990;65:269-74.
  Romero M, Kapur G, Baracco R, Valentini RP, Mattoo TK, Jain A. Treatment of Hypertension in Children With Catecholamine-Secreting Tumors: A Systematic Approach. Journal of Clinical Hypertension. 2015;17:720-5.
  Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, Chun RH, Garzon MC, Holland KE, Liberman L, MacLellan-Tobert S, Mancini AJ, Metry D, Puttgen KB, Seefeldt M, Sidbury R, Ward KM, Blei F, Baselga E, Cassidy L, Darrow DH, Joachim S, Kwon EKM, Martin K, Perkins J, Siegel DH, Boucek RJ, Frieden IJ. Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference. Pediatrics. 2013;131:128-40.
  Filippi L, Cavallaro G, Fiorini P, Malvagia S, Della Bona ML, Giocaliere E, Bagnoli P, Dal Monte M, Mosca F, Donzelli G, la Marca G. Propranolol concentrations after oral administration in term and preterm neonates. J Matern Fetal Neonatal Med. 2013;26:833-40.
  Australian Medicines Handbook. Accessed 05/09/2018: https://amhonline.amh.net.au.acs.hcn.com.au/
  MIMSOnline. Accessed 05/09/2018: https://www.mimsonline.com.au.acs.hcn.com.au/
  van der Kaay DC, Wasserman JD, Palmert MR. Management of neonates born to mothers with Graves’ disease. Pediatrics. 2016 Apr 1;137(4):e20151878.
  LaFranchi S, Geffner ME, Hoppin AG. Evaluation and management of neonatal Graves’ disease. UptoDate online. Accessed on 11 April 2019.
  Ogilvy-Stuart AL. Neonatal thyrotoxicosis. Neoreviews. 2017 Jul 1;18(7):e422-30.
  Markham LA, Stevens DL. A case report of neonatal thyrotoxicosis due to maternal autoimmune hyperthyroidism. Adv Neonat Care. 2003;3:272-82; quiz 83-5.
  Smith C, Thomsett M, Choong C, Rodda C, McIntyre HD, Cotterill AM. Congenital thyrotoxicosis in premature infants. Clin Endocrinol (Oxf). 2001;54:371-6.
  |
  |
  | |